PNT - POINT Biopharma Global - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $16.95. This is a potential upside of $4.45 (35.6%) from yesterday's end of day stock price of $12.5.

POINT Biopharma Global's activity chart (see below) currently has 29 price targets and 22 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 35% with an average time for these price targets to be met of 75.5 days.

Most recent stock forecast was given by KEMP DOLLIVER from BROOKLINE on 21-Dec-2023.

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$12.5

$27

1 years 9 months 13 days ago
(21-Dec-2023)

1/3 (33.33%)

$0.03 (0.24%)

5

Hold

$12.5

$17

1 years 11 months 10 days ago
(24-Oct-2023)

1/3 (33.33%)

$-0.16 (-1.26%)

55

Hold

$13

1 years 11 months 28 days ago
(06-Oct-2023)

2/2 (100%)

$3.73 (40.24%)

156

Hold

$12.5

$14

2 years ago
(04-Oct-2023)

2/3 (66.67%)

$0.1 (0.81%)

199

Hold

$22

2 years 1 days ago
(04-Oct-2023)

0/1 (0%)

$13.49 (158.52%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is PNT (POINT Biopharma Global) average time for price targets to be met?

On average it took 75.5 days on average for the stock forecasts to be realized with a an average price target met ratio 35

Which analyst has the current highest performing score on PNT (POINT Biopharma Global) with a proven track record?

JAMES EDWARDES JONES

Which analyst has the most public recommendations on PNT (POINT Biopharma Global)?

James Edwardes Jones works at RBC and has 0 price targets and 0 ratings on PNT

Which analyst is the currently most bullish on PNT (POINT Biopharma Global)?

Suji Jeong with highest potential upside - $7.5

Which analyst is the currently most reserved on PNT (POINT Biopharma Global)?

Edward Tenthoff with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?